The Wall Street Journal Highlights the CF Foundation’s Drug Development Efforts
| 1 min read

The Wall Street Journal today features an article, “Disease Charities Pursue Cures by Investing in Drug Start-Ups.” It credits the Foundation for motivating other non-profits to fund promising early-stage drug research with drug companies.

According to the article, charities are “…inspired by the success of the Cystic Fibrosis Foundation in spurring numerous companies to work on potential treatments for the rare genetic disease that kills most patients before the age of 40.”

The article mentions the Foundation's collaboration with Vertex Pharmaceuticals Inc., involving two promising therapies known as VX-770 and VX-809.  

Read the full article.

Share this article
About the CF Foundation | Drug Pipeline
Recent news
CF Foundation Invests Up to $2 Million in Nanite Inc. to Explore a New Method to Deliver Genetic Therapies to the Lung
News | 2 min read
More Than 175 Advocates Urge Action During 16th Annual March on the Hill
News | 3 min read
Journal of CF Highlights Cost Burden Prevalent in the Cystic Fibrosis Community
News | 4 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.